Dalvance
Named-patient access overview. Dalvance is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Dalvance (dalbavancin) is a long-acting intravenous lipoglycopeptide antibiotic marketed by AbbVie. The US Food and Drug Administration approved Dalvance in May 2014 for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) in adults and, since July 2021, in paediatric patients from birth, caused by susceptible Gram-positive organisms including methicillin-resistant Staphylococcus aureus. The approved adult regimen is either a single 1500 mg intravenous infusion over 30 minutes or 1000 mg followed one week later by 500 mg. The long half-life supports outpatient parenteral antimicrobial therapy and short hospital stays under an infectious diseases specialist.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Dalvance
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Dalvance is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Dalvance in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Dalvance
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.